10x Genomics Stock Investor Sentiment

TXG Stock  USD 10.69  0.09  0.83%   
Roughly 66% of 10X Genomics' investor base is looking to short. The analysis of overall sentiment of trading 10X Genomics stock suggests that many investors are alarmed at this time. The current market sentiment, together with 10X Genomics' historical and current headlines, can help investors time the market. In addition, many technical investors use 10X Genomics stock news signals to limit their universe of possible portfolio assets.

Comfort Level 34

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use 10X Genomics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward 10X Genomics.

10X Historical Sentiment

Although 10X Genomics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding 10X, such as negative comments on social media and news outlets, may cause fear in the market and push 10X Genomics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of 10X.
  

10X Genomics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards 10X Genomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

10X Genomics Historical Investor Sentiment

Investor biases related to 10X Genomics' public news can be used to forecast risks associated with an investment in 10X. The trend in average sentiment can be used to explain how an investor holding 10X can time the market purely based on public headlines and social activities around 10X Genomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
10X Genomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for 10X Genomics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average 10X Genomics news discussions. The higher the estimate score, the more favorable the investor's outlook on 10X Genomics.

10X Genomics Maximum Pain Price Across May 16th 2025 Option Contracts

10X Genomics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of 10X Genomics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of 10X Genomics' options.
over three months ago at benzinga.com         
Gene Sequencing Tech Provider 10x Genomics Q3 Sales Fall Short On Expectations, But CEO Sees Opportu...
benzinga news
over three months ago at finance.yahoo.com         
Gene Sequencing Tech Provider 10x Genomics Q3 Sales Fall Short On Expectations, But CEO Sees Opportu...
Yahoo News
over three months ago at thelincolnianonline.com         
10x Genomics Trading Up 5.2 percent Heres Why
news
over three months ago at finance.yahoo.com         
10x Genomics Announces Preliminary Select Third Quarter 2024 Results
Yahoo News
over three months ago at gurufocus.com         
10x Genomics Inc Q2 2024 Earnings Call Highlights Navigating Growth Amidst Macroeconomic ...
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
10x Genomics Inc Stock Price Up 3.83 percent on Oct 8
Gurufocus Stories at Macroaxis
over three months ago at simplywall.st         
Shareholders in 10x Genomics have lost 87, as stock drops 12 percent this past week
Simply Wall St News at Macroaxis
over three months ago at gurufocus.com         
Vanguard Groups Strategic Acquisition in 10x Genomics Inc
Gurufocus Stories at Macroaxis
over three months ago at gurufocus.com         
10x Genomics Inc Shares Down 5.87 percent on Oct 2
Gurufocus Stories at Macroaxis
over three months ago at finance.yahoo.com         
10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas Gen...
Yahoo News
over three months ago at news.google.com         
Susquehanna Fundamental Investments LLC Has 3.92 Million Holdings in 10x Genomics, Inc. - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
Short Interest in 10x Genomics, Inc. Declines By 12.6 percent - MarketBeat
Google News at Macroaxis
over three months ago at news.google.com         
10x Genomics short call reiterated at Hedgeye, sees potential for 50 percent downside - Seeking Alph...
Google News at Macroaxis
over three months ago at gurufocus.com         
10x Genomics Inc Shares Down 5.27 percent on Sep 25
Gurufocus Stories at Macroaxis
over three months ago at finance.yahoo.com         
10x Genomics investors are sitting on a loss of 85 percent if they invested three years ago
Yahoo News
Far too much social signal, news, headlines, and media speculation about 10X Genomics that are available to investors today. That information is available publicly through 10X media outlets and privately through word of mouth or via 10X internal channels. However, regardless of the origin, that massive amount of 10X data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of 10X Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 10X Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 10X Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 10X Genomics alpha.

10X Genomics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 441 shares by Justin McAnear of 10X Genomics at 55.0641 subject to Rule 16b-3
12/06/2024
2
Disposition of 4660 shares by Serge Saxonov of 10X Genomics at 43.9959 subject to Rule 16b-3
01/31/2025
3
Cathie Wood dumped Palantir to buy these biotech stocks
02/06/2025
4
Insider Trading
02/07/2025
5
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
02/12/2025
6
Q4 2024 10X Genomics Inc Earnings Call Transcript
02/13/2025
7
10x Genomics Downgraded by Leerink Partnrs to Hold
02/14/2025
8
10x Genomics to Participate in the 45th Annual TD Cowen Health Care Conference
02/18/2025
9
10x Genomics, Inc. Receives Consensus Recommendation of Hold from Analysts
02/26/2025
10
Serge Saxonov Sells 5,092 Shares of 10x Genomics, Inc. Stock
02/28/2025

Complementary Tools for 10X Stock analysis

When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Fundamental Analysis
View fundamental data based on most recent published financial statements
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like